AnalystsInsight

Steven Lichtman (William Blair): Analyst Track Record and Price‑Target Accuracy

How often Steven Lichtman’s price targets were reached, how fast, and what the stocks did after each call: a 7‑year backtest of 631 ratings, compared with the average Wall Street analyst.

Published Updated 3 min readHow we research

What changed since Oct 12

Exent re-checks this page every day. Ratings appear 30 days after they are published; live calls are in Gems.

+3 new ratings (BFLY, BBNX, MMED)

Key takeaways

  • Steven Lichtman ranks #529 of 1,000 analysts in Exent’s scoring (4.8★).
  • 47.2% of price targets were reached over 7 years, versus 52.4% for the average analyst.
  • Median time to reach a target: 92 days; 59.8% of calls were up 12 months later.
  • Most‑covered stocks: DXCM, RXST, ZBH, MDT.
  • Free on Exent: Steven Lichtman’s full record, with ratings 3 days after publication.

Steven Lichtman’s track record at a glance

Steven Lichtman of William Blair ranks #529 of the 1,000 analysts Exent scores, with a 4.8★ rating and a focus on healthcare. Over a 7‑year lookback, 47.2% of Steven’s price targets were reached, 5.2 points below the 52.4% average across all analysts.

MetricSteven LichtmanAll analysts
Price‑target hit rate47.2%52.4%
Median days to hit target92 days91 days
Calls up after 12 months59.8%64.0%
Median 12‑month return of calls+9.1%+13.4%
Hit rate, last 2 years25.9%—
Average worst drop after a call−22.5%—
Ratings in the sample631—
Stocks covered26—

The full records of Exent’s top 90 analysts and the top 50 of each sector, and the stocks where several of them agree right now, are members‑only in Exent Gems.

How fast price targets were reached

Time to reach the targetSteven Lichtman
Under 30 days22.6%
30–90 days25.0%
90–180 days32.3%
Over 180 days20.2%

Share of the targets that were reached, by how long they took. Targets are usually set for 12 months.

Stocks Steven Lichtman covers most

StockRatings in the sample
DXCM40
RXST39
ZBH31
MDT31
GKOS24
BSX23
PODD20
MNKD20

In the past year Steven’s ratings were 72% Buy, 28% Hold and 0% Sell.

Steven Lichtman’s latest ratings

DateStockActionRatingPrice target
Sep 15, 2026BFLYReiterated: BuyBuy$0.00
Sep 14, 2026BBNXReiterated: HoldHold$0.00
Sep 14, 2026MMEDReiterated: BuyBuy$0.00
Sep 12, 2026COODowngraded: HoldHold$0.00
Sep 9, 2026SYKReiterated: BuyBuy$0.00
Sep 2, 2026MMEDReiterated: BuyBuy$0.00
Aug 25, 2026MMEDReiterated: BuyBuy$0.00
Aug 21, 2026BBNXInitiated Coverage: HoldHold$0.00
Aug 21, 2026TNDMInitiated Coverage: BuyBuy$0.00
Aug 18, 2026COOReiterated: BuyBuy$0.00
Aug 14, 2026ENOVReiterated: BuyBuy$0.00
Aug 12, 2026OWLTReiterated: BuyBuy$0.00
  • Sep 15, 2026
    Stock
    BFLY
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $0.00
  • Sep 14, 2026
    Stock
    BBNX
    Action
    Reiterated: Hold
    Rating
    Hold
    Price target
    $0.00
  • Sep 14, 2026
    Stock
    MMED
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $0.00
  • Sep 12, 2026
    Stock
    COO
    Action
    Downgraded: Hold
    Rating
    Hold
    Price target
    $0.00
  • Sep 9, 2026
    Stock
    SYK
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $0.00
  • Sep 2, 2026
    Stock
    MMED
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $0.00
  • Aug 25, 2026
    Stock
    MMED
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $0.00
  • Aug 21, 2026
    Stock
    BBNX
    Action
    Initiated Coverage: Hold
    Rating
    Hold
    Price target
    $0.00
  • Aug 21, 2026
    Stock
    TNDM
    Action
    Initiated Coverage: Buy
    Rating
    Buy
    Price target
    $0.00
  • Aug 18, 2026
    Stock
    COO
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $0.00
  • Aug 14, 2026
    Stock
    ENOV
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $0.00
  • Aug 12, 2026
    Stock
    OWLT
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $0.00

Steven’s ratings are free on Exent 3 days after publication. Exent Gems has them the same day, with the calls of the top‑ranked analysts and the stocks where several of them agree.

How Exent scores analysts

Exent replays every rating with a price target over a 7‑year lookback: was the target reached, how long it took, and what the stock returned 1, 3, 6 and 12 months after the call. The star rating and rank combine success rate, average return and the number of ratings, so a few lucky calls do not make a top analyst. Statistics as of Jun 24, 2026; ranking updated Oct 20, 2026. How accurate are analyst price targets overall?

Past performance does not guarantee future results. Historical figures are calculated by Exent from market data and are for education only; they are not investment advice or a recommendation to buy or sell any security.

Follow the analysts with the best records

  1. Exent Gems shows Steven Lichtman’s live ratings and those of the top‑ranked analysts, without the 30‑day delay used on this page.
  2. Gems are the stocks where several 4★+ analysts agree: Exent’s shortlist of high‑conviction ideas.
  3. Check any idea against your own portfolio: correlation, concentration and crash exposure before you buy.

Exent is our product. Educational content, not investment advice.

Frequently asked questions

By Exent’s scoring Steven Lichtman ranks #529 of 1,000 with a 4.8★ rating. 47.2% of price targets were reached over a 7-year lookback (all analysts: 52.4%), and 59.8% of calls were up 12 months later. Past accuracy does not guarantee future accuracy.

Steven Lichtman’s success rate is 53.1% by the ranking source and 47.2% by Exent’s price-target hit-rate backtest, with a median of 92 days to reach a target.

Steven Lichtman (William Blair) covers 26 stocks, mostly in healthcare. The most frequently rated are DXCM, RXST, ZBH, MDT, GKOS.

Get the picks Wall Street’s best analysts agree on.

Exent tracks 4,000+ analysts, keeps only the elite few with proven records, and surfaces the Gems where they agree.

See this week’s GemsLimited offer$1.95 for full access· full access

Educational content, not investment advice. Examples are illustrative; past performance does not guarantee future results.

DISCLAIMER: Exent AI is an informational research platform and does not provide investment advice, financial advice, or act as an investment adviser, broker-dealer, or fiduciary. All content, analytics, and model outputs are provided for educational and informational purposes only and should not be relied upon as a recommendation to buy, sell, or hold any financial instrument. Investing involves risk, including the possible loss of principal. Exent AI does not execute trades, hold customer funds, or provide brokerage services. Past performance and hypothetical results are not indicative of future results. Third-party data and AI-generated outputs may be incomplete or inaccurate.